Jensen I M, Hokland M, Hokland P
University Department of Haematology and Medicine, Arhus Amtssygehus, Denmark.
Leuk Res. 1993 Oct;17(10):839-46. doi: 10.1016/0145-2126(93)90149-f.
By staining human bone marrow cells with a monoclonal antibody reacting with erythroid precursor cells (AS-E1) and propidium iodide, we have evaluated the proliferative capacity of erythropoiesis in patients with myelodysplastic syndromes (MDS) using flow cytometry. Comparing 36 patients (13 RA/RAS, 13 RAEB, 10 RAEB-t) with 7 normal controls, significant differences in both the percentage of AS-E1+ cells and the fraction of AS-E1+ cells in the S or S-G2M-phase between the four groups were found. Since neither the percentage of AS-E1+ cells nor their fraction in S or S-G2M alone was found to characterize their proliferative activity, we introduced the proliferative fractions of the erythroid cell, i.e. the number of the AS-E1+ cells in S or S-G2M related to all bone marrow cells in S or S-G2M. Applying these parameters, we found significantly increased proliferative AS-E1 fractions in the RA/RAS group compared to the normal controls (p = 0.03 and 0.002) respectively, as well as a highly significant decrease with disease progression.
通过用与红系前体细胞反应的单克隆抗体（AS-E1）和碘化丙啶对人骨髓细胞进行染色，我们使用流式细胞术评估了骨髓增生异常综合征（MDS）患者红系造血的增殖能力。将36例患者（13例RA/RAS、13例RAEB、10例RAEB-t）与7名正常对照进行比较，发现四组之间AS-E1+细胞百分比以及处于S期或S-G2M期的AS-E1+细胞比例均存在显著差异。由于发现单独的AS-E1+细胞百分比及其在S期或S-G2M期的比例均不能表征其增殖活性，我们引入了红系细胞的增殖分数，即处于S期或S-G2M期的AS-E1+细胞数量与处于S期或S-G2M期的所有骨髓细胞数量的比值。应用这些参数，我们发现RA/RAS组与正常对照相比，增殖性AS-E1分数分别显著增加（p = 0.03和0.002），并且随着疾病进展显著降低。
